广泛的基因开关和对化物有毒性耐药性蛋白质的化物
Jenny L Baker1, Narasimhan Sudarsan2,3, Zasha Weinberg2,3
1Department of Chemistry, Yale University, Box 208103, New Haven, CT 06520, USA.
概括
科学家们在细菌和古生物中发现了新的化物 рибо开关. 这些RNA结构感知并响应化物,控制有助于生物管理有毒化物水平的基因.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 丝带切换器是调节性RNA元素,通常在细菌信使RNA中发现.
- 它们通过与小分子 (代谢物) 结合来控制基因表达.
- 响应特定环境线索的许多 рибо开关的功能在很大程度上仍未被描述.
研究的目的:
- 为了发现和描述新的 рибо交换机类.
- 研究 рибо开关在感知环境离子,特别是化物中的作用.
- 了解细菌和古生物用来应对化物暴露的遗传和细胞机制.
主要方法:
- 细菌和古生物基因组的生物信息分析,以确定保存的RNA结构.
- 在体外测试测试,以测试已识别的riboswitch对各种离子的结合特异性.
- 记者基因测试测量了对化物反应中的 рибо开关的调节活性.
主要成果:
- 发现了一种由离子选择性激活的新类 рибо开关.
- 这些化物 рибо开关存在于各种细菌和古生物物种中.
- рибо开关调节涉及化物运输和代谢的基因,以及功能不明的蛋白质.
结论:
- 许多生物体暴露在有毒水平的化物中.
- 化物感应的 рибо开关是一种广泛的机制,用于控制对化物反应的基因表达.
- 这些基于RNA的传感器在细胞适应化物压力方面发挥着至关重要的作用.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Transduction
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome are...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...


